ADVERTISEMENT

Sponsored CE/CME

Individualizing Statin Therapy
This supplement is sponsored by Primary Care Education Consortium and the Primary Care Metabolic Group and was supported by an educational grant by Kowa Pharmaceuticals America, Inc. and Lilly USA, LLC.
Fewer than 20% of patients with coronary heart disease are at their low-density lipoprotein cholesterol goal. This supplement reviews risk factors and treatment goals for dyslipidemia characterized by high low-density lipoprotein cholesterol. Emphasis is placed on statin therapy, with a focus on recently published results of clinical trials with long-term follow-up, as well as on pitavastatin, the newest statin. Differences among the statins, clinically important adverse events and drug interactions, and strategies to improve adherence are also discussed.










Download PDF



Physicians and Physician Assistants – Click Here to Take the Test
Nurse Practitioners – Click Here to Take the Test
Solving Clinical Conundrums with Incretin-Based Therapy in Type 2 Diabetes
This supplement is sponsored by the Illinois Academy of Family Physicians and the Primary Care Metabolic Group and was supported by an educational grant by Novo Nordisk, Inc.
Incretin-based therapies are recommended treatment options for the management of patients with type 2 diabetes. In addition to differences with other glucose-lowering agents, there are important differences between and among the glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. These differences, and their clinical relevance, are discussed with suggestions offered to address common conundrums faced in managing patients with type 2 diabetes using incretin-based therapy.










Download PDF



Physicians and Physician Assistants – Click Here to Take the Test
Nurse Practitioners – Click Here to Take the Test
PAGEPrev | 1 | Next
Quick Poll
Which of the following is NOT in the differential for heparin-induced thrombocytopenia?



Submit Answer
View Results
Most Popular